Belite Bio to Present Data at Euretina and EIS Conferences
News related to:Belite Bio · 2 min read
SAN DIEGO, Sept. 28, 2026 /CourierPR/ -- Belite Bio, a clinical-stage drug development company focused on advancing novel therapeutics for degenerative retinal diseases, will present its data at two upcoming medical conferences in Vienna, Austria.
On September 30, 2026, at the Euretina Innovation Spotlight (EIS), Hendrik Scholl, M.D., Chief Medical Officer of Belite Bio, will provide an overview of the company. The presentation will take place from 2:28 to 3:06 p.m. Central European Summer Time (CEST) in Room 1/Hall A of the Vienna Congress & Convention Center.
The second presentation will occur on October 4, 2026, at the EURETINA conference. Michel Michaelides, M.D., from Moorfields Eye Hospital and the UCL Institute of Ophthalmology in London, United Kingdom, will present top-line results from the Phase 3 DRAGON study of Tinlarebant for adolescent Stargardt disease. This presentation will be held from 1:20 to 1:27 p.m. CEST in the Free Paper Forum 2.
Tinlarebant, also known as LBS-008, is a novel oral therapy designed to reduce the accumulation of vitamin A-based toxins, known as bisretinoids, that contribute to retinal disease in Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD). The therapy works by modulating the amount of retinol entering the eye, thereby reducing the formation of bisretinoids. Tinlarebant has received several designations, including Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.
Belite Bio's lead candidate, Tinlarebant, has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint. The company's new drug application for Tinlarebant for the treatment of STGD1 was accepted by the U.S. Food and Drug Administration (FDA) with priority review, with a Prescription Drug User Fee Act (PDUFA) date set for February 12, 2027. Tinlarebant is also currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA.
The presentations at Euretina and EIS will provide valuable insights into the progress of Belite Bio's research and development efforts in treating degenerative retinal diseases.